WO1995002067A1 - Procede ameliore de quantification de l'acide nucleique - Google Patents
Procede ameliore de quantification de l'acide nucleique Download PDFInfo
- Publication number
- WO1995002067A1 WO1995002067A1 PCT/EP1994/002295 EP9402295W WO9502067A1 WO 1995002067 A1 WO1995002067 A1 WO 1995002067A1 EP 9402295 W EP9402295 W EP 9402295W WO 9502067 A1 WO9502067 A1 WO 9502067A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- sample
- analyte
- amounts
- constructs
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 276
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 271
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 271
- 238000000034 method Methods 0.000 title claims abstract description 96
- 238000011002 quantification Methods 0.000 title claims abstract description 42
- 239000012491 analyte Substances 0.000 claims abstract description 102
- 230000003321 amplification Effects 0.000 claims abstract description 74
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 74
- 238000006243 chemical reaction Methods 0.000 claims abstract description 29
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 13
- 239000000523 sample Substances 0.000 claims description 91
- 238000002955 isolation Methods 0.000 claims description 50
- 238000001514 detection method Methods 0.000 claims description 29
- 239000012530 fluid Substances 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 238000007865 diluting Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 62
- 238000002474 experimental method Methods 0.000 description 26
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 22
- 238000007792 addition Methods 0.000 description 22
- 230000003612 virological effect Effects 0.000 description 20
- 238000000338 in vitro Methods 0.000 description 18
- 239000000203 mixture Substances 0.000 description 15
- 238000003556 assay Methods 0.000 description 13
- 239000011324 bead Substances 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 10
- 238000011109 contamination Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000012895 dilution Substances 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 239000012139 lysis buffer Substances 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- BZSVVCFHMVMYCR-UHFFFAOYSA-N 2-pyridin-2-ylpyridine;ruthenium Chemical compound [Ru].N1=CC=CC=C1C1=CC=CC=N1.N1=CC=CC=C1C1=CC=CC=N1.N1=CC=CC=C1C1=CC=CC=N1 BZSVVCFHMVMYCR-UHFFFAOYSA-N 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000013381 RNA quantification Methods 0.000 description 3
- WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6865—Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
Definitions
- each construct being distinguishable from the analyte nucleic acid and capable of being co-amplified with the analyte nucleic acid
- reaction aliquots, each of a known volume, to each of which nucleic acid constructs are added in different ranges of amounts. Preferably, in that case, to each reaction volume the same nucleic acid constructs are added. If, for example, two reactions are used, a "low-range” reaction and a “high range” reaction can be carried out. For example, when the ranges of nucleic acid
- Contaminations with about 100-1000 molecules will slightly influence the internal calibration line and will only interfere with the calculation of the amount of analyte nucleic acid molecules present in the sample if the amount of analyte molecules in the sample is less than 1000 molecules. Contaminations with more than 1000 molecules will alter the calibration line and the outcome of the calculation.
- log (Q/A) log (Q/A)
- nucleic acid amplification procedure may be added, said quantity expected to be within the same range as the expected amount of analyte nucleic acid present in said sample, subjecting the sample to a nucleic acid amplification procedure, using
- pGEM3Q C ⁇ gag3 Q C -RNA
- SP6 RNA polymerase SP6 RNA polymerase
- the cloned inserts of pGEM3p24 and pGEM3Q A were recloned into vector pGEM4 creating pGEM4p24 and pGEM4Q A .
- Using these plasmids in vitro RNA was made using T7 RNA polymerase (Sambrook, 1989).
- the length of the in vitro RNA is 1514 nucleotides for plasmids pGEM3p24 (WT-RNA) and pGEM3Q A (Q A -RNA) and 1090 nucleotides for plasmids
- the number of amplification reactions can be decreased with the method according to the invention where several distinguishable internal standards are spiked into one amplification.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- AIDS & HIV (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU74928/94A AU668659B2 (en) | 1993-07-09 | 1994-07-08 | Improved method for the quantification of nucleic acid |
JP50383695A JP3594598B2 (ja) | 1993-07-09 | 1994-07-08 | 改良された核酸定量方法 |
DE69417863T DE69417863T2 (de) | 1993-07-09 | 1994-07-08 | Verbessertes verfahren für die quantifizierung von nukleinsäuren |
DK94924750T DK0662156T3 (da) | 1993-07-09 | 1994-07-08 | Forbedret fremgangsmåde til kvantificering af nukleinsyre |
CA002143857A CA2143857C (fr) | 1993-07-09 | 1994-07-08 | Methode amelioree pour le dosage de l'acide nucleique |
KR1019950700919A KR100312800B1 (ko) | 1993-07-09 | 1994-07-08 | 핵산의정량방법 |
EP94924750A EP0662156B1 (fr) | 1993-07-09 | 1994-07-08 | Procede ameliore de quantification de l'acide nucleique |
FI951082A FI112094B (fi) | 1993-07-09 | 1995-03-08 | Parannettu menetelmä nukleiinihapon kvantitoimiseksi |
GR990401631T GR3030554T3 (en) | 1993-07-09 | 1999-06-17 | Improved method for the quantification of nucleic acid. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93202015.9 | 1993-07-09 | ||
EP93202015 | 1993-07-09 | ||
EP93203424.2 | 1993-12-06 | ||
EP93203424 | 1993-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995002067A1 true WO1995002067A1 (fr) | 1995-01-19 |
Family
ID=26133903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1994/002295 WO1995002067A1 (fr) | 1993-07-09 | 1994-07-08 | Procede ameliore de quantification de l'acide nucleique |
Country Status (10)
Country | Link |
---|---|
JP (1) | JP3594598B2 (fr) |
KR (1) | KR100312800B1 (fr) |
AT (1) | ATE178946T1 (fr) |
AU (1) | AU668659B2 (fr) |
CA (1) | CA2143857C (fr) |
DE (1) | DE69417863T2 (fr) |
DK (1) | DK0662156T3 (fr) |
ES (1) | ES2131699T3 (fr) |
FI (1) | FI112094B (fr) |
WO (1) | WO1995002067A1 (fr) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0714988A2 (fr) * | 1994-09-26 | 1996-06-05 | IMMUNO Aktiengesellschaft | Procédé pour quantifier d'acides nucléiques |
EP0722508A1 (fr) * | 1993-09-22 | 1996-07-24 | Igen, Inc. | Dosage d'acides nucleiques electrochimioluminescents par replication de sequences auto-entretenues |
EP0747488A1 (fr) * | 1995-06-07 | 1996-12-11 | Gen-Probe Incorporated | Procédés et trousse des détection des taux de pre-amplification d'une séquence cible d'acide nucléique à partir des taux de post-amplification des produits |
WO1997012058A1 (fr) * | 1995-09-26 | 1997-04-03 | Dynal A/S | Procede de quantification d'acide nucleique consistant a utiliser plusieurs acides nucleiques concurrents |
US5705365A (en) * | 1995-06-07 | 1998-01-06 | Gen-Probe Incorporated | Kits for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product |
WO1998000547A1 (fr) * | 1996-07-03 | 1998-01-08 | Ambion, Inc. | Preparation et utilisation d'arn resistant a la ribonuclease |
US5710029A (en) * | 1995-06-07 | 1998-01-20 | Gen-Probe Incorporated | Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product |
WO1998041650A2 (fr) * | 1997-03-18 | 1998-09-24 | Visible Genetics Inc. | Procede et trousse de quantification et de sequençage d'acide nucleique d'analytes d'acide nucleique dans un echantillon |
FR2765590A1 (fr) * | 1997-07-01 | 1999-01-08 | Pasteur Institut | Methode de semi-quantification d'alleles |
US5919625A (en) * | 1996-07-03 | 1999-07-06 | Ambion, Inc. | Ribonuclease resistant viral RNA standards |
WO2000000638A2 (fr) * | 1998-06-26 | 2000-01-06 | Akzo Nobel N.V. | Marquage d'amplicons d'arn produits au moyen d'une amplification fondee sur la transcription |
EP1013776A1 (fr) * | 1998-12-22 | 2000-06-28 | Universiteit van Amsterdam | Méthode sensible d'essai pour la détection ou pour la quantification d'acide nucléique de cytomégalovirus humain |
WO2000046401A1 (fr) * | 1999-02-03 | 2000-08-10 | Lgc (Teddington) Limited | Materiau de reference pour amplification d'acide nucleique |
WO2001007661A2 (fr) * | 1999-07-23 | 2001-02-01 | Gen-Probe Incorporated | Methode d'amplification de polynucleotides |
WO2001046463A2 (fr) * | 1999-12-22 | 2001-06-28 | Baxter Aktiengesellschaft | Methodes de preparation et d'utilisation d'etalons internes destines a des dosages par amplification de l'acide nucleique |
EP1319716A1 (fr) * | 2000-09-22 | 2003-06-18 | Hitachi, Ltd. | Procede d'analyse d'acide nucleique |
EP1352091A2 (fr) * | 2000-12-22 | 2003-10-15 | Cepheid | Compositions et procedes permettant la surveillance interne totale de la reaction par amplification |
US7972778B2 (en) | 1997-04-17 | 2011-07-05 | Applied Biosystems, Llc | Method for detecting the presence of a single target nucleic acid in a sample |
WO2012114312A3 (fr) * | 2011-02-25 | 2012-11-01 | Novartis Ag | Témoin positif interne exogène |
US8889405B2 (en) | 2009-09-16 | 2014-11-18 | Seiko Epson Corporation | Biochip and target DNA quantitative method |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5564795B2 (ja) * | 2009-01-06 | 2014-08-06 | 株式会社島津製作所 | Dna定量方法、及び遺伝子解析方法 |
KR102108855B1 (ko) | 2017-10-30 | 2020-05-12 | 한국표준과학연구원 | 안정동위원소 표지 핵산을 내부표준물질로 활용하는 핵산 정량 방법 및 이의 용도 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0303459A2 (fr) * | 1987-08-11 | 1989-02-15 | The President And Fellows Of Harvard College | Séquenage multiplexe |
EP0525882A1 (fr) * | 1991-08-02 | 1993-02-03 | Akzo Nobel N.V. | Quantification d'acides nucléiques |
WO1993010257A1 (fr) * | 1991-11-15 | 1993-05-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Procede de determination de la quantite d'un fragment d'adn d'interet par une methode d'amplification enzymatique d'adn |
-
1994
- 1994-07-08 DK DK94924750T patent/DK0662156T3/da active
- 1994-07-08 DE DE69417863T patent/DE69417863T2/de not_active Expired - Lifetime
- 1994-07-08 AT AT94924750T patent/ATE178946T1/de active
- 1994-07-08 AU AU74928/94A patent/AU668659B2/en not_active Expired
- 1994-07-08 CA CA002143857A patent/CA2143857C/fr not_active Expired - Lifetime
- 1994-07-08 JP JP50383695A patent/JP3594598B2/ja not_active Expired - Lifetime
- 1994-07-08 WO PCT/EP1994/002295 patent/WO1995002067A1/fr active IP Right Grant
- 1994-07-08 KR KR1019950700919A patent/KR100312800B1/ko not_active Expired - Lifetime
- 1994-07-08 ES ES94924750T patent/ES2131699T3/es not_active Expired - Lifetime
-
1995
- 1995-03-08 FI FI951082A patent/FI112094B/fi not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0303459A2 (fr) * | 1987-08-11 | 1989-02-15 | The President And Fellows Of Harvard College | Séquenage multiplexe |
EP0525882A1 (fr) * | 1991-08-02 | 1993-02-03 | Akzo Nobel N.V. | Quantification d'acides nucléiques |
WO1993010257A1 (fr) * | 1991-11-15 | 1993-05-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Procede de determination de la quantite d'un fragment d'adn d'interet par une methode d'amplification enzymatique d'adn |
Non-Patent Citations (2)
Title |
---|
APOSTOLAKOS ET AL., ANALYTICAL BIOCHEMISTRY, vol. 213, September 1993 (1993-09-01), NEW YORK US, pages 277 - 284 * |
GEMEN ET AL., JOURNAL OF VIROLOGICAL METHODS, vol. 43, July 1993 (1993-07-01), AMSTERDAM NL, pages 177 - 188 * |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0722508A1 (fr) * | 1993-09-22 | 1996-07-24 | Igen, Inc. | Dosage d'acides nucleiques electrochimioluminescents par replication de sequences auto-entretenues |
EP0722508A4 (fr) * | 1993-09-22 | 1999-08-11 | Igen Inc | Dosage d'acides nucleiques electrochimioluminescents par replication de sequences auto-entretenues |
EP0714988A2 (fr) * | 1994-09-26 | 1996-06-05 | IMMUNO Aktiengesellschaft | Procédé pour quantifier d'acides nucléiques |
EP0714988A3 (fr) * | 1994-09-26 | 1997-04-16 | Immuno Ag | Procédé pour quantifier d'acides nucléiques |
US5789153A (en) * | 1994-09-26 | 1998-08-04 | Immuno Aktiengesellschaft | Method of quantitating nucleic acid |
EP0747488A1 (fr) * | 1995-06-07 | 1996-12-11 | Gen-Probe Incorporated | Procédés et trousse des détection des taux de pre-amplification d'une séquence cible d'acide nucléique à partir des taux de post-amplification des produits |
WO1996040990A1 (fr) * | 1995-06-07 | 1996-12-19 | Gen-Probe Incorporated | Procedes et trousses servant a determiner les niveaux de preamplification d'une sequence cible d'acides nucleiques a partir des niveaux de post-amplification du produit |
US5705365A (en) * | 1995-06-07 | 1998-01-06 | Gen-Probe Incorporated | Kits for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product |
AU709292B2 (en) * | 1995-06-07 | 1999-08-26 | Gen-Probe Incorporated | Methods and kits for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product |
US5710029A (en) * | 1995-06-07 | 1998-01-20 | Gen-Probe Incorporated | Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product |
WO1997012058A1 (fr) * | 1995-09-26 | 1997-04-03 | Dynal A/S | Procede de quantification d'acide nucleique consistant a utiliser plusieurs acides nucleiques concurrents |
US5919625A (en) * | 1996-07-03 | 1999-07-06 | Ambion, Inc. | Ribonuclease resistant viral RNA standards |
US6214982B1 (en) | 1996-07-03 | 2001-04-10 | Ambion Inc | Ribonuclease resistant RNA preparation and utilization |
US6399307B1 (en) | 1996-07-03 | 2002-06-04 | Ambion, Inc. | Methods of quantifying viral load in an animal with a ribonuclease resistant RNA preparation |
US7033749B2 (en) | 1996-07-03 | 2006-04-25 | Ambion, Inc. | Ribonuclease resistant RNA preparation and utilization |
WO1998000547A1 (fr) * | 1996-07-03 | 1998-01-08 | Ambion, Inc. | Preparation et utilisation d'arn resistant a la ribonuclease |
US5939262A (en) * | 1996-07-03 | 1999-08-17 | Ambion, Inc. | Ribonuclease resistant RNA preparation and utilization |
WO1998041650A2 (fr) * | 1997-03-18 | 1998-09-24 | Visible Genetics Inc. | Procede et trousse de quantification et de sequençage d'acide nucleique d'analytes d'acide nucleique dans un echantillon |
WO1998041650A3 (fr) * | 1997-03-18 | 1999-01-14 | Visible Genetics Inc | Procede et trousse de quantification et de sequençage d'acide nucleique d'analytes d'acide nucleique dans un echantillon |
US8859204B2 (en) | 1997-04-17 | 2014-10-14 | Applied Biosystems, Llc | Method for detecting the presence of a target nucleic acid sequence in a sample |
US8822183B2 (en) | 1997-04-17 | 2014-09-02 | Applied Biosystems, Llc | Device for amplifying target nucleic acid |
US8563275B2 (en) | 1997-04-17 | 2013-10-22 | Applied Biosystems, Llc | Method and device for detecting the presence of a single target nucleic acid in a sample |
US8551698B2 (en) | 1997-04-17 | 2013-10-08 | Applied Biosystems, Llc | Method of loading sample into a microfluidic device |
US8278071B2 (en) | 1997-04-17 | 2012-10-02 | Applied Biosystems, Llc | Method for detecting the presence of a single target nucleic acid in a sample |
US8257925B2 (en) | 1997-04-17 | 2012-09-04 | Applied Biosystems, Llc | Method for detecting the presence of a single target nucleic acid in a sample |
US8067159B2 (en) | 1997-04-17 | 2011-11-29 | Applied Biosystems, Llc | Methods of detecting amplified product |
US9506105B2 (en) | 1997-04-17 | 2016-11-29 | Applied Biosystems, Llc | Device and method for amplifying target nucleic acid |
US7972778B2 (en) | 1997-04-17 | 2011-07-05 | Applied Biosystems, Llc | Method for detecting the presence of a single target nucleic acid in a sample |
FR2765590A1 (fr) * | 1997-07-01 | 1999-01-08 | Pasteur Institut | Methode de semi-quantification d'alleles |
WO1999001575A1 (fr) * | 1997-07-01 | 1999-01-14 | Institut Pasteur De Lille | Methode de semi-quantification d'alleles |
WO2000000638A2 (fr) * | 1998-06-26 | 2000-01-06 | Akzo Nobel N.V. | Marquage d'amplicons d'arn produits au moyen d'une amplification fondee sur la transcription |
WO2000000638A3 (fr) * | 1998-06-26 | 2000-04-20 | Akzo Nobel Nv | Marquage d'amplicons d'arn produits au moyen d'une amplification fondee sur la transcription |
EP1013776A1 (fr) * | 1998-12-22 | 2000-06-28 | Universiteit van Amsterdam | Méthode sensible d'essai pour la détection ou pour la quantification d'acide nucléique de cytomégalovirus humain |
WO2000037678A1 (fr) * | 1998-12-22 | 2000-06-29 | Universiteit Van Amsterdam | Analyse sensible destinee a la detection ou la quantification d'un acide nucleique du cytomegalovirus humain |
WO2000046401A1 (fr) * | 1999-02-03 | 2000-08-10 | Lgc (Teddington) Limited | Materiau de reference pour amplification d'acide nucleique |
US6908735B2 (en) | 1999-07-23 | 2005-06-21 | Gen-Probe Incorporated | Polynucleotide quantitation method |
AU781570B2 (en) * | 1999-07-23 | 2005-06-02 | Gen-Probe Incorporated | Polynucleotide amplification method |
WO2001007661A2 (fr) * | 1999-07-23 | 2001-02-01 | Gen-Probe Incorporated | Methode d'amplification de polynucleotides |
WO2001007661A3 (fr) * | 1999-07-23 | 2002-07-11 | Gen Probe Inc | Methode d'amplification de polynucleotides |
WO2001046463A3 (fr) * | 1999-12-22 | 2002-06-27 | Baxter Ag | Methodes de preparation et d'utilisation d'etalons internes destines a des dosages par amplification de l'acide nucleique |
WO2001046463A2 (fr) * | 1999-12-22 | 2001-06-28 | Baxter Aktiengesellschaft | Methodes de preparation et d'utilisation d'etalons internes destines a des dosages par amplification de l'acide nucleique |
EP1319716A1 (fr) * | 2000-09-22 | 2003-06-18 | Hitachi, Ltd. | Procede d'analyse d'acide nucleique |
US7790368B1 (en) | 2000-09-22 | 2010-09-07 | Hitachi, Ltd. | Method for analyzing nucleic acid |
EP1319716A4 (fr) * | 2000-09-22 | 2005-01-12 | Hitachi Ltd | Procede d'analyse d'acide nucleique |
EP1352091A4 (fr) * | 2000-12-22 | 2004-07-21 | Cepheid | Compositions et procedes permettant la surveillance interne totale de la reaction par amplification |
EP1352091A2 (fr) * | 2000-12-22 | 2003-10-15 | Cepheid | Compositions et procedes permettant la surveillance interne totale de la reaction par amplification |
US8889405B2 (en) | 2009-09-16 | 2014-11-18 | Seiko Epson Corporation | Biochip and target DNA quantitative method |
US9388467B2 (en) | 2009-09-16 | 2016-07-12 | Seiko Epson Corporation | Biochip and target DNA quantitative method |
US9416418B2 (en) | 2009-09-16 | 2016-08-16 | Seiko Epson Corporation | Biochip and target DNA quantitative method |
WO2012114312A3 (fr) * | 2011-02-25 | 2012-11-01 | Novartis Ag | Témoin positif interne exogène |
US9580761B2 (en) | 2011-02-25 | 2017-02-28 | Novartis Ag | Exogenous internal positive control |
Also Published As
Publication number | Publication date |
---|---|
DK0662156T3 (da) | 1999-10-25 |
ES2131699T3 (es) | 1999-08-01 |
JPH08501222A (ja) | 1996-02-13 |
ATE178946T1 (de) | 1999-04-15 |
FI951082A0 (fi) | 1995-03-08 |
AU668659B2 (en) | 1996-05-09 |
FI951082A (fi) | 1995-03-08 |
FI112094B (fi) | 2003-10-31 |
AU7492894A (en) | 1995-02-06 |
DE69417863D1 (de) | 1999-05-20 |
JP3594598B2 (ja) | 2004-12-02 |
KR100312800B1 (ko) | 2002-02-28 |
CA2143857A1 (fr) | 1995-01-19 |
CA2143857C (fr) | 2005-09-20 |
DE69417863T2 (de) | 1999-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5837501A (en) | Nucleic acid quantitation by co-amplification of target with multiple internal controls | |
AU668659B2 (en) | Improved method for the quantification of nucleic acid | |
Mulder et al. | Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection | |
EP0972077B1 (fr) | Procede et trousse de quantification et de sequencage d'acide nucleique d'analytes d'acide nucleique dans un echantillon | |
US5800984A (en) | Nucleic acid sequence detection by triple helix formation at primer site in amplification reactions | |
US6541205B1 (en) | Method for assaying nucleic acid | |
JP2846018B2 (ja) | 核酸配列の増幅および検出 | |
EP0623682B1 (fr) | ContrÔles internes pour réactions d'amplification isotherme d'acide nucléique | |
US5106727A (en) | Amplification of nucleic acid sequences using oligonucleotides of random sequences as primers | |
CA2299275C (fr) | Sequences nucleotidiques pouvant etre utilisees comme amorces et comme sondes au cours de l'amplification et de la detection de tous les sous-types du vih-1 | |
US7384769B2 (en) | Method for the quantitative detection of nucleic acids | |
US20030157499A1 (en) | Method of assessing the amount of nucleic acid in a sample | |
Mercier et al. | Simultaneous screening for HBV DNA and HCV RNA genomes in blood donations using a novel TaqMan PCR assay | |
US20020137039A1 (en) | 5' Nuclease nucleic acid amplification assay having an improved internal control | |
EP3330385A1 (fr) | Procédés et compositions pour la détection quantitative de séquences d'acides nucléiques sur une plage dynamique étendue | |
WO1993002215A1 (fr) | Amplification quantitative de l'acide nucleique | |
JP2001515734A (ja) | 非競合的共増幅法 | |
JP4209977B2 (ja) | 淋菌の核酸の増幅および検出による淋菌の検出 | |
EP1426448A1 (fr) | Procédé pour réduire les effects des variations de séquence dans un procédé d'hybridisation diagnostique, sonde de l'usage dans un tel procédé, et procédé | |
WO1997012058A1 (fr) | Procede de quantification d'acide nucleique consistant a utiliser plusieurs acides nucleiques concurrents | |
US6830887B2 (en) | Method and kit for quantitation and nucleic acid sequencing of nucleic acid analytes in a sample | |
EP0662156B1 (fr) | Procede ameliore de quantification de l'acide nucleique | |
CN113957176A (zh) | 鉴别新冠病毒变异株和野生株的检测试剂、反应体系及试剂盒和用途 | |
CN102165077A (zh) | 降低诊断杂交测定中对靶核酸的序列变异的依赖性的方法 | |
RU2350650C2 (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pVar15-HIV-LTR, НЕСУЩАЯ КЛОНИРОВАННЫЙ ФРАГМЕНТ ГЕНОМА ВИЧ-1 ТИПА ИЗ КОНСЕРВАТИВНОГО УЧАСТКА 5'-LTR ПОСЛЕДОВАТЕЛЬНОСТИ, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBluKSM-HIV-LTR mod, НЕСУЩАЯ КЛОНИРОВАННЫЙ МОДИФИЦИРОВАННЫЙ ФРАГМЕНТ ЭТОГО ЖЕ УЧАСТКА ГЕНОМА ВИЧ-1 ТИПА, ТЕСТ-НАБОР ДЛЯ КОЛИЧЕСТВЕННОЙ ЭКСПРЕСС-ИДЕНТИФИКАЦИИ ГЕНОМА ВИЧ-1 ЛЮБОГО ТИПА В ПРОБЕ И СПОСОБ С ЕГО ИСПОЛЬЗОВАНИЕМ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994924750 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2143857 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1995 397172 Country of ref document: US Date of ref document: 19950308 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 951082 Country of ref document: FI |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1994924750 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1996 661340 Country of ref document: US Date of ref document: 19960612 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 1997 938499 Country of ref document: US Date of ref document: 19970926 Kind code of ref document: A |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994924750 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 951082 Country of ref document: FI |